论文部分内容阅读
目的探讨奥氮平治疗帕金森病并发精神障碍的临床疗效及安全性。方法选取徐州市东方人民医院2014年5月—2016年5月收治的帕金森病并发精神障碍患者80例,随机分为对照组和观察组,各40例。对照组患者采用常规药物治疗,观察组患者在对照组基础上给予奥氮平片治疗,两组患者均持续治疗2个月。比较两组患者治疗前后精神状态量表(SAPS)评分、运动功能评分量表(UPDRS)评分、临床疗效,观察患者不良反应发生情况。结果治疗前,两组患者怪异行为、妄想、幻觉评分比较,差异无统计学意义(P>0.05);治疗后,观察组患者怪异行为、妄想、幻觉评分低于对照组(P<0.05)。两组患者治疗前后UPDRS评分比较,差异无统计学意义(P>0.05)。观察组患者临床疗效优于对照组(P<0.05)。两组患者均未出现严重不良反应。结论采用奥氮平治疗帕金森病并发精神障碍的临床疗效确切,可有效缓解患者的精神症状,且安全性高。
Objective To investigate the clinical efficacy and safety of olanzapine in the treatment of Parkinson’s disease complicated by mental disorders. Methods Eighty patients with Parkinson’s disease complicated by mental disorder admitted to Xuzhou Oriental People’s Hospital from May 2014 to May 2016 were randomly divided into control group and observation group, 40 cases in each group. Patients in the control group were treated with conventional drugs. Patients in the observation group were treated with olanzapine on the basis of the control group, and both groups were treated for 2 months. The scores of SAPS, UPDRS, clinical curative effect were compared between the two groups before and after treatment to observe the occurrence of adverse reactions. Results Before treatment, there was no significant difference between the two groups in weird behavior, delusion and hallucination score (P> 0.05). After treatment, the scores of weird behavior, delusion and hallucination in the observation group were lower than those in the control group (P <0.05). There was no significant difference in UPDRS scores between the two groups before and after treatment (P> 0.05). The clinical efficacy of the observation group was better than that of the control group (P <0.05). No serious adverse reactions occurred in both groups. Conclusion The clinical efficacy of olanzapine in the treatment of Parkinson’s disease complicated with mental disorders is exact and can effectively alleviate the patients’ mental symptoms and is safe.